Vistagen Therapeutics CEO Shawn Singh joined Steve Darling from Proactive to share news about the company that is a late-stage biopharmaceutical company based in South San Francisco, focusing on transforming the treatment options for anxiety disorders, depression disorders, and other neurological disorders. They have developed a new class of drugs called "pherines" that are administered as nasal sprays. These drugs target specific receptors in the nose that connect to parts of the brain associated with mood disorders.
Singh telling Proactive its lead drug, fasedienol or PH94B, has received FDA Fast Track designation for social anxiety disorder. The company has several other assets in their pipeline and plans to advance them through phase three programs.